Sjögren's disease & overlap diseases
Treatment modalities of marginal zone lymphoma and overall survival, haematological response, and underlying Sjögren's disease activity: a multicentre, retrospective, observational study
Main finding · New SjD systemic activity (marginal zone lymphoma)Result — go to the resultHazard ratio 0.43 95% CI 0.21–0.90Authors' conclusion
A systemic treatment strategy for Sjögren's disease-associated lymphoma, rather than localised treatment or a watch and wait strategy, reduces the risk of new Sjögren's disease systemic activity and combination therapy is associated with decreased risk of lymphoma relapse.
Study context
- Population
- Patients with SjD (2016 ACR-EULAR criteria) who developed lymphoma diagnosed before Jan 1, 2020; two expert centres in Paris, the French ASSESS cohort and Club Rhumatismes et Inflammation practitioners
- Participants
- 50 / 13 / 19 / 32 / 18
- Exposure
- Systemic treatment vs localised treatment or watch and wait at lymphoma diagnosis; chemotherapy plus anti-CD20 combination vs monotherapy as first-line therapy
- Systemic treatmentn = 50
- Localised treatmentn = 13reference
- Watch and waitn = 19reference
- Combination therapyn = 32
- Monotherapyn = 18reference
- Outcome
- Effect of lymphoma treatment on three endpoints: lymphoma progression-free survival, new SjD systemic activity, and overall survival
Methodological detailsmulticentre, observational, inverse probability of treatment weighting
- Multicentre
- Observational
- Inverse probability of treatment weighting
Main finding
As reported in the abstract
Hazard ratio
0.43
95% CI 0.21–0.90
Observational data: associations, not effects.
Further findings
| Outcome | HR for lymphoma progression (95% CI) | |
|---|---|---|
| Lymphoma progression-free survival, first-line combination therapyvs monotherapyInverse probability of treatment weighting | 0.36 (0.14–0.94) | |
| 0.10.31310HR for lymphoma progression (log scale) |
Mortality by pulmonary localisation (MZL, exploratory multivariable analysis)
| HR for death (95% CI) | ||
|---|---|---|
| Pulmonary localisationMultivariable analysis | 7.92 (1.70–37.0) | |
| 0.050.21520HR for death (log scale) |
New SjD systemic activity and overall survival, combination therapy vs monotherapy
- No differences in new SjD systemic activity or overall survival according to combination therapy or monotherapy
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →